CDTX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	199 489
Średni wolumen	58 335.00
Kapitalizacja rynkowa	57.61M
EPS	$0 ( 2024-03-28 )
Następna data zysków	( $-1.500 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.43
ATR14	$0.0870 (0.69%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Ward Shane	Buy	120 000	Common Stock
2024-03-15	Ward Shane	Buy	250 000	Employee Stock Option (right to buy)
2024-03-15	Shah Preetam	Buy	108 750	Common Stock
2024-03-15	Shah Preetam	Buy	217 500	Employee Stock Option (right to buy)
2024-03-15	Tari Leslie	Buy	111 250	Common Stock

INSIDER POWER
89.46
Last 100 transactions
Buy: 7 175 633 \| Sell: 576 273

Wolumen Korelacja

Długi: -0.10 (neutral)

Krótki: -0.27 (neutral)

Signal:(38.021) Neutral

Cidara Therapeutics Inc Korelacja

10 Najbardziej pozytywne korelacje
MESA	0.902
ATHX	0.885
CTIB	0.882
IGTA	0.876
HLIO	0.873
IOBT	0.859
XLNX	0.857
TITN	0.855
KZR	0.854
AZYO	0.853

10 Najbardziej negatywne korelacje
NTUS	-0.89
DVCR	-0.876
OPNT	-0.869
JJSF	-0.867
SVOK	-0.866
LMNX	-0.861
PROC	-0.856
STAY	-0.852
DSPG	-0.843
MSON	-0.842

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cidara Therapeutics Inc Korelacja - Waluta/Towar

0.49
( neutral )

0.48
( neutral )

0.00
( neutral )

-0.13
( neutral )

0.22
( neutral )

-0.27
( neutral )

Cidara Therapeutics Inc Finanse

Annual	2023
Przychody:	$63.91M
Zysk brutto:	$62.38M (97.62 %)
EPS:	$-0.260

FY	2023
Przychody:	$63.91M
Zysk brutto:	$62.38M (97.62 %)
EPS:	$-0.260

FY	2022
Przychody:	$64.29M
Zysk brutto:	$64.15M (99.78 %)
EPS:	$-0.430

FY	2021
Przychody:	$49.57M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

Cidara Therapeutics Inc

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.